ABBV Earnings

1 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $668 Million; Global Juvederm Net Revenues Were $232 Million • Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28, which Includes an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Th

o an excellent start in 2026, with first-quarter results exceeding our expectations. AbbVie’s key growth drivers continue to deliver strong performance and support our enhanced full-year outlook,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “We are also generating exciting data and advancing numerous programs across all stages of deve

41 per share related to acquired IPR&D and milestones expense incurred year-to-date through the first quarter 2026. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2026, as both cannot be reliably forecasted.

arnings per share guidance for 2026 previously announced on February 4, 2026 excluded the impact of acquired IPR&D and milestones expense that may be incurred in 2026. AbbVie’s full-year 2026 adjusted diluted earnings per share guidance range, including the impact of first quarter 2026 acquired IPR&D and milestones expense, is $13.

ooking statements as a result of subsequent events or developments, except as required by law. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Guidance including the impact of acquired IPR&D and milestones expense . 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

: 26838123 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences) EX-99.1 2 abbv-20260331nonxgaapxex991.htm EX-99.1 Document AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended March 31, 2026 Full-Year Ended December 31, 2026 Ac